Drug Sponsors

McKesson acquires Celesio

Friday, January 24, 2014 11:44 AM

McKesson, a North American healthcare services and information technology company, has reached an agreement with Franz Haniel to acquire its entire holding of Celesio shares for $32.24 per share. In a separate and subsequent agreement, McKesson announced the acquisition of Celesio convertible bonds from Elliott. These agreements are not subject to any closing conditions and the transactions are expected to close within 10 business days. After the close of the agreements, McKesson will own more than 75% of Celesio shares on a fully diluted basis.

More... »

NuPathe terminates agreement with Endo, to be acquired by Teva

Wednesday, January 22, 2014 12:28 PM

NuPathe, a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system, has terminated its agreement and plan to merge with Endo Health Solutions, and its board has withdrawn its recommendation that stockholders accept Endo's offer to acquire all outstanding shares of NuPathe common stock.

More... »


Aurobindo acquires commercial operations in seven countries from Actavis

Monday, January 20, 2014 11:59 AM

Aurobindo Pharma, a Hyderabad, India-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has signed a binding offer to acquire commercial operations in seven Western European countries from Actavis, a Dublin, Ireland-based global, integrated specialty pharmaceutical company. Closing of the transaction is conditional on certain antitrust approvals and completion of employee consultation processes.

More... »

Carlyle Group makes binding offer to acquire J&J’s Ortho-Clinical Diagnostics

Friday, January 17, 2014 11:34 AM

Johnson & Johnson has received a binding offer from the Carlyle Group to acquire its Ortho-Clinical Diagnostics business for $4.15 billion. Ortho-Clinical Diagnostics delivers in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner.

More... »

Oligomerix relocates, secures lab space from New York Medical College

Wednesday, January 15, 2014 11:11 AM

Oligomerix, a privately-held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, has relocated its corporate headquarters to Valhalla, N.Y. as of Jan. 15, and expanded a lease agreement for additional laboratory space at New York Medical College.

More... »

Moderna launches Onkaido Therapeutics

Wednesday, January 15, 2014 10:59 AM

Moderna Therapeutics, a developer of messenger RNA (mRNA) therapeutics, a treatment modality to enable the in vivo production of therapeutic proteins, has created Onkaido Therapeutics, a new venture focused exclusively on developing mRNA-based oncology treatments.

More... »

Sanofi, Fraunhofer-Gesellschaft create natural product center of excellence

Wednesday, January 15, 2014 10:57 AM

Sanofi and Fraunhofer-Gesellschaft, a European organization for applied research, have launched a natural product center of excellence to accelerate the discovery and development of new therapies to treat infectious diseases, the second leading cause of mortality worldwide, accounting for 10 million deaths in 2011.

More... »

Crealta Pharmaceuticals acquires Savient Pharmaceuticals

Tuesday, January 14, 2014 10:00 AM

Crealta Pharmaceuticals, a new specialty pharmaceutical company, has acquired substantially all of the assets of Savient Pharmaceuticals. Crealta previously announced winning an auction for these assets, signing a definitive acquisition agreement with Savient and the subsequent approval of the transaction by the U.S. Bankruptcy Court for the District of Delaware.

More... »

Regeneron launches new human genetics initiative

Tuesday, January 14, 2014 08:00 AM

Regeneron Pharmaceuticals, a science-based biopharmaceutical company based in Tarrytown, N.Y., has launched a new human genetics initiative via a new wholly owned subsidiary, the Regeneron Genetics Center (RGC).

More... »

goBalto expands internationally

Monday, January 13, 2014 11:48 AM

goBalto, a provider of clinical study start-up solutions, has opened its first international locations, in Singapore and the U.K.

More... »

Link to survey



Browse by:


November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs